Evidence map›Paper›PMID 42726730›Full record

ArticleCancer medicine2026

Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3-Rearranged Renal Cell Carcinoma: A Multicenter Real-World Study.

Shuxuan Zhu, Siqi Zhou, Xi Tian, Jun Wang, Ze Wang, Jun Jiang, Qiuli Liu, Xin Gou, Xiang Zhou, Jun Gu and 11 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Shuxuan ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0009-0000-6763-8381
Siqi ZhouDepartment of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Xi TianDepartment of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0003-1965-0647
Jun WangDepartment of Urology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
Ze WangDepartment of Urology, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.
Jun JiangDepartment of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.ORCID https://orcid.org/0000-0001-9408-2972
Qiuli LiuDepartment of Urology, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.ORCID https://orcid.org/0000-0002-9532-5654
Xin GouDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.ORCID https://orcid.org/0000-0003-3062-209X
Xiang ZhouDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Jun GuThe Affiliated Jiangsu Shengze Hospital, Nanjing Medical University, Suzhou, People's Republic of China.
Jianfeng YangDepartment of Urology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0002-9526-2438
Jianhui ChenDepartment of Urology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Shushang ChenDepartment of Urology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China.
Wenfeng WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Aihetaimujiang AnwaierDepartment of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0002-0859-5171
Kun ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
Yuanyuan QuDepartment of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0003-1179-2800
James BrugarolasDivision of Hematology-Oncology, Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
Wenhao XuDepartment of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0002-0660-9162
Hailiang ZhangDepartment of Urology, Huadong Hospital, Fudan University, Shanghai, People's Republic of China.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0002-6761-5195

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-HR2020MS-0948National Natural Science Foundation of China 82172741National Natural Science Foundation of China 82473192Scientific Innovation Project of Shanghai Education Committee 2021-01-07-00-07-E00080Shanghai Anti-Cancer Association Eyas Project SACA-CY23A02Shanghai Anti-Cancer Association Eyas Project SACA-CY23C04Shanghai Municipal Health Bureau 2020CXJQ03
6 · The paper itself

Abstract

backgroundTFE3-rearranged renal cell carcinoma (TFE3-rRCC) is uncommon and encompasses biologically diverse tumors, while evidence to guide systemic treatment remains sparse. We examined clinical outcomes, treatment patterns, and molecular features in a multicenter real-world cohort.

methodsWe reviewed 151 patients with TFE3-rRCC treated at eight centers in China. Treatment analyses included the 59 patients who had metastatic or relapsed disease and sufficiently detailed treatment records. Response was assessed by RECIST version 1.1. Kaplan-Meier methods were used for time-to-event outcomes, and potential confounding was explored with Cox regression.

resultsMedian first-line progression-free survival (PFS) was 6.1 months among the 59 treated patients. PFS was longer with first-line ICI/TKI therapy than with TKI monotherapy (log-rank p = 0.034). In an exploratory multivariable model, distant lymph-node metastasis was associated with shorter overall survival (HR, 5.22; 95% CI, 1.17-23.40; p = 0.031). In a small subgroup comparison, NONO-TFE3 tumors had a relatively immune-depleted transcriptomic profile and lower disease control with ICI/TKI therapy.

conclusionsTFE3-rRCC is a heterogeneous disease with poor survival and a variable therapeutic response. ICI/TKI combinations had modest activity; newer approaches are needed.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, Renal CellGene RearrangementKidney NeoplasmsAdultAgedFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedProgression-Free SurvivalProtein Kinase InhibitorsRetrospective StudiesTreatment OutcomeBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsImmune Checkpoint InhibitorsProtein Kinase InhibitorsTFE3 protein, humanfusion partnerreal‐world studysystemic therapyTFE3‐rearranged renal cell carcinomatranslocation renal cell carcinoma

Identifiers

PMID42726730
PMCPMC13567803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.